Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predicting type 2 diabetes and testosterone effects in high-risk Australian men: development and external validation of a 2-year risk model.
Robledo KP, Marschner IC, Grossmann M, Handelsman DJ, Yeap BB, Allan CA, Foote C, Inder WJ, Stuckey BGA, Jesudason D, Bracken K, Keech AC, Jenkins AJ, Gebski V, Jardine M, Wittert G. Robledo KP, et al. Among authors: allan ca. Eur J Endocrinol. 2025 Jan 6;192(1):15-24. doi: 10.1093/ejendo/lvae166. Eur J Endocrinol. 2025. PMID: 39720906 Clinical Trial.
Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trial.
Wittert G, Atlantis E, Allan C, Bracken K, Conway A, Daniel M, Gebski V, Grossmann M, Hague W, Handelsman DJ, Inder W, Jenkins A, Keech A, McLachlan R, Robledo K, Stuckey B, Yeap BB. Wittert G, et al. Diabetes Obes Metab. 2019 Apr;21(4):772-780. doi: 10.1111/dom.13601. Epub 2019 Jan 4. Diabetes Obes Metab. 2019. PMID: 30520208
Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.
Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, Stuckey B, Conway A, Inder W, McLachlan R, Allan C, Jesudason D, Fui MNT, Hague W, Jenkins A, Daniel M, Gebski V, Keech A. Wittert G, et al. Lancet Diabetes Endocrinol. 2021 Jan;9(1):32-45. doi: 10.1016/S2213-8587(20)30367-3. Lancet Diabetes Endocrinol. 2021. PMID: 33338415 Clinical Trial.
Testosterone Treatment, Weight Loss, and Health-related Quality of Life and Psychosocial Function in Men: A 2-year Randomized Controlled Trial.
Grossmann M, Robledo KP, Daniel M, Handelsman DJ, Inder WJ, Stuckey BGA, Yeap BB, Ng Tang Fui M, Bracken K, Allan CA, Jesudason D, Zajac JD, Wittert GA. Grossmann M, et al. Among authors: allan ca. J Clin Endocrinol Metab. 2024 Jul 12;109(8):2019-2028. doi: 10.1210/clinem/dgae085. J Clin Endocrinol Metab. 2024. PMID: 38335137 Free PMC article. Clinical Trial.
Higher serum undercarboxylated osteocalcin and other bone turnover markers are associated with reduced diabetes risk and lower estradiol concentrations in older men.
Yeap BB, Alfonso H, Chubb SA, Gauci R, Byrnes E, Beilby JP, Ebeling PR, Handelsman DJ, Allan CA, Grossmann M, Norman PE, Flicker L. Yeap BB, et al. Among authors: allan ca. J Clin Endocrinol Metab. 2015 Jan;100(1):63-71. doi: 10.1210/jc.2014-3019. J Clin Endocrinol Metab. 2015. PMID: 25365314 Free article.
Telephone call reminders did not increase screening uptake more than SMS reminders: a recruitment study within a trial.
Bracken K, Keech A, Hague W, Kirby A, Robledo KP, Allan C, Conway A, Daniel M, Gebski V, Grossmann M, Handelsman DJ, Inder W, Jenkins A, McLachlan R, Stuckey B, Yeap BB, Wittert G. Bracken K, et al. J Clin Epidemiol. 2019 Aug;112:45-52. doi: 10.1016/j.jclinepi.2019.04.009. Epub 2019 Apr 30. J Clin Epidemiol. 2019. PMID: 31051248 Clinical Trial.
64 results